American Society of Clinical Oncology

SHERPA: White

People

  1. Heller
    Heller
  2. Scher
    Scher
  3. Morris
    Morris
  4. Fox
    Fox
  5. Schoder
    Schoder
  6. Slovin
    Slovin
  7. Autio
    Autio
  8. Humm
    Humm
  9. Schwartz
    Schwartz
  10. Bajorin
    Bajorin

Groups

  1. Biostatistics Service (7)
  2. Department of Medicine (7)
  3. Epidemiology and Biostatistics (7)
  4. GSK Faculty (7)
  5. Genitourinary Oncology Service (7)
  6. Molecular Imaging and Therapy Service (7)
  7. Molecular Pharmacology and Chemistry Program Faculty (7)
  8. Radiology, Department of (7)
  9. Sloan Kettering Institute Faculty (7)
  10. Solid Tumor Oncology Division (7)
Search Within
  1. "Glenn Heller"
  2. "Steven Larson"
Formats
  1. Meeting Abstract (4)
  2. Journal Article (3)
Groups
  1. Biostatistics Service (7)
  2. Department of Medicine (7)
  3. Epidemiology and Biostatistics (7)
  4. GSK Faculty (7)
  5. Genitourinary Oncology Service (7)
  6. Molecular Imaging and Therapy Service (7)

More Groups

People
  1. Glenn Heller (7)
  2. Howard Scher (7)
  3. Steven Larson (7)
  4. Michael Morris (5)
  5. Heiko Schoder (4)
  6. Josef Fox (4)

More People

Years
  1. 2014 (1)
  2. 2012 (2)
  3. 2010 (1)
  4. 2009 (1)
  5. 2007 (1)
  6. 2001 (1)
Publications
  1. Journal of Clinical Oncology (7)

Results (7)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Evaluating 18F-16 beta-fluoro-5 alpha-dihydrotestosterone (FDHT) and FDG PET as prognostic biomarkers for patients (pts) treated with abiraterone acetate (AA)
    Meeting Abstract

    Feldman, J. L.; Fox, J. J.; Autio, K. A.; Gavane, S. C.; Heller, G.; Schoder, H.; Humm, J.; Martinez, D. F.; Slovin, S. F.; Scher, H. I.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • 18F-16 beta-fluoro-5 alpha-dihydrotestosterone (FDHT) PET as a prognostic biomarker for survival in patients with metastatic castrate-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Autio, K. A.; Fox, J. J.; Jia, X.; Heller, G.; Schoder, H.; Humm, J.; Haupt, E. C.; Schneider, C.; Scher, H. I.; Larson, S. M.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Bone scan index: A quantitative treatment response biomarker for castration-resistant metastatic prostate cancer
    Journal Article

    Dennis, E. R.; Jia, X.; Mezheritskiy, I. S.; Stephenson, R. D.; Schoder, H.; Fox, J. J.; Heller, G.; Scher, H. I.; Larson, S. M.; Morris, M. J.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Fluorodeoxyglycose (FDG) PET as an outcome measure for metastatic prostate cancer
    Meeting Abstract

    Morris, M. J.; Fox, J. J.; Dennis, E. R.; Tse, K.; Flatts, E.; Heller, G.; Jia, X.; Schoder, H.; Larson, S. M.; Scher, H. I.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer
    Journal Article

    Morris, M. J.; Pandit-Taskar, N.; Carrasquillo, J.; Divgi, C. R.; Slovin, S.; Kelly, W. K.; Rathkopf, D.; Gignac, G. A.; Solit, D.; Schwartz, L.; more...
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Circulating tumor cells in patients with castration-resistant metastatic prostate cancer
    Meeting Abstract

    Danila, D. C.; Leversha, M. A.; Gonzalez-Espinoza, R.; Anand, A.; Gu, B.; Gignac, G. A.; Larson, S.; Heller, G.; Fleisher, M.; Scher, H. I.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer
    Journal Article

    Kelly, W. K.; Curley, T.; Slovin, S.; Heller, G.; McCaffrey, J.; Bajorin, D.; Ciolino, A.; Regan, K.; Schwartz, M.; Kantoff, P.; more...
    Journal of Clinical Oncology (2001)

    Fulltext@MSK | Save